About PharmaCyte Biotech
PharmaCyte Biotech (NASDAQ:PMCB) is a biotech firm focusing on developing cellular therapies for cancer and diabetes using its unique live-cell encapsulation technology, Cell-in-a-Box®. This technology is designed to encase living cells that can convert inactive chemotherapy drugs into their active or cancer-killing form directly at the site of the cancer. PharmaCyte's primary project revolves around utilizing its technology for the treatment of inoperable pancreatic cancer, aiming to improve patient outcomes and quality of life. The company is also exploring the potential of Cell-in-a-Box® in the development of treatments for diabetes, with the goal of creating a bio-artificial pancreas for insulin-dependent diabetics. PharmaCyte's objectives include advancing its clinical trials and research, forming strategic partnerships, and achieving regulatory milestones to become a leader in cell-based therapies.
Snapshot
Operations
Products and/or services of PharmaCyte Biotech
- Cell-in-a-Box technology for cancer treatment, utilizing live cells to convert prodrugs into their active cancer-killing forms.
- Encapsulation of live cells for insulin production, aiming at a novel diabetes treatment approach.
- Clinical research focusing on pancreatic cancer, employing targeted chemotherapy methods.
- Development of therapies for solid tumor cancers, leveraging encapsulated cells for localized treatment.
- Partnerships for advancing drug delivery systems, enhancing efficacy and safety of chemotherapy.
- Investigations into treatments for malignant ascites, exploring less invasive and more effective solutions.
PharmaCyte Biotech executive team
- Mr. Joshua N. SilvermanCEO. President & Executive Chairman
- Mr. Carlos A. Trujillo CPAChief Financial Officer
- Dr. Jose L. Iglesias M.D.Consulting Chief Medical Officer
- Dr. Hans-Peter Hammes M.D.Member of Medical & Scientific Advisory Board and Consultant